LGD-4033 (Ligandrol)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

LGD-4033 (Ligandrol)

A selective androgen receptor modulator investigated in clinical trials but not FDA-approved for human use.

Evidence category: Preclinical. This describes the source category, not approval or certainty.

Regulatory statement in source: Not FDA-approved.

LGD-4033 (Ligandrol) is a selective androgen receptor modulator developed by Ligand Pharmaceuticals. A Phase I trial (Basaria et al. 2013) in 76 healthy men found dose-dependent lean mass gains over 21 days. Despite extensive human trials (over 25 controlled studies, 1,700+ subjects), no SARM has received FDA approval.

Benefits reported in the imported source

• Selective androgen receptor activity in muscle and bone
• Lean mass gains demonstrated in short-term study

Risks and limits

• Limited long-term human safety data
• Suppression of endogenous testosterone

Source bottom line: Preclinical and early-stage research only; no FDA approval despite extensive clinical trials on 1,700+ subjects.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 24–36 hours. Basaria et al. 2013, J Gerontol A Biol Sci Med Sci 68(1):87-95, PMID 22459616 — Phase 1 human PK trial Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Basaria et al. 2013, J Gerontol A Biol Sci Med Sci - PubMed
• LGD-4033 SARM Research - Ligand Pharmaceuticals
• LGD-4033 - Wikipedia